News
Mauna Kea Technologies Announces Publication of Positive Results on Needle-Based Endomicroscopy for the Clinical Management of Pancreatic Cystic Lesions
Regulatory News:
Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) inventor of Cellvizio®, the multidisciplinary probe- and needle-based confocal laser endomicroscopy (pCLE/nCLE) platform, today
Healthcare Improvement Company Premier Inc. to Present at 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Jan. 14
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, announced today that its Chief Executive Officer, Susan DeVore, will present at the 38th Annual J.P. Morgan Healthcare
Application Process for 2020 Louisville-Based Community Partners Program Opens
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 38 years, today announced the details of its 2020 Community Partners Program. Through this initiative, The Humana
Xencor and Gilead Enter License Agreement for Use of XmAb® Antibody Technologies in Investigational Agents for HIV
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases
Evotec: Das hören Anleger gern
Es sind Meldungen wie diese, die Anleger in Evotec-Aktien (WKN: 566480) jubeln lassen. Wie gestern bekannt gegeben, erweitert Evotec die Forschungsallianz mit dem Global Player Bristol-Myers Squibb
Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of
NANOBIOTIX Announces Plan for Global Phase III Head and Neck Cancer Registration Trial Along With Overall Development Update
Regulatory News:
“After the achievement of major development milestones in 2019, 2020 offers great opportunity for Nanobiotix and NBTXR3 to fulfill unmet patient needs across oncology. Given
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 38th Annual J.P. Morgan
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 38th Annual J.P. Morgan
Clovis Oncology Announces Product Revenues for the Fourth Quarter and Full Year 2019
Clovis
Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary,
unaudited revenues for the fourth quarter and full year ended December
31, 2019. The financial
Clovis Oncology Announces Debt Refinancing Transaction
Clovis Oncology, Inc. (NASDAQ: CLVS) (the “Company”) announced today that on January 6, 2020 it priced a registered direct offering (the “Share Offering”) of an aggregate of 17,777,679 shares (the
Transgene and NEC Start Two Clinical Trials with TG4050, an Individualized AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TSE:
The Medicines Company Announces Effective Date Of Make-Whole Fundamental Change Relating To Its 2.50% Convertible Senior Notes Due 2022, 2.75% Convertible Senior Notes due 2023 and 3.50% Convertible Senior Notes due 2024
The Medicines Company (the “Company”) today provided notice of a Make-Whole Fundamental Change to holders of its (i) 2.50% Convertible Senior Notes due 2022 (the “2022 Notes”), (ii) 2.75%
Premier Inc. Analysis: Complications & Common Chronic Conditions Increase Hospitals’ Childbirth Costs by 20 Percent or More
U.S. hospitals could save upwards of 20 percent in costs for complicated childbirths, according to a nationally representative analysis by Premier Inc. (NASDAQ: PINC). The increased costs
Dexcom to Present at 38th Annual J.P. Morgan Healthcare Conference
DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 38th annual J.P. Morgan Healthcare
Dexcom to Present at 38th Annual J.P. Morgan Healthcare Conference
DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 38th annual J.P. Morgan Healthcare
Illumina and Pacific Biosciences Announce Termination of Merger Agreement
Illumina, Inc. (NASDAQ:ILMN) and Pacific Biosciences of California, Inc. (NASDAQ:PACB) today announced that they have mutually agreed to terminate their merger agreement, previously announced on
Illumina and Pacific Biosciences Announce Termination of Merger Agreement
Illumina, Inc. (NASDAQ:ILMN) and Pacific Biosciences of California, Inc. (NASDAQ:PACB) today announced that they have mutually agreed to terminate their merger agreement, previously announced on
Illumina and Pacific Biosciences Announce Termination of Merger Agreement
Illumina, Inc. (NASDAQ:ILMN) and Pacific Biosciences of California, Inc. (NASDAQ:PACB) today announced that they have mutually agreed to terminate their merger agreement, previously announced on
NanoString to Present at the 38th Annual JP Morgan Healthcare Conference
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research, today announced that the company’s management is scheduled to present at the 38th
Pulmatrix: NBC-Empfehlung explodiert nach Big-Pharma-Deal
Für den No Brainer Club überträgt sich das gigantische Momentum von Ende 2019 ohne Unterbrechung ins neue Jahr: Mit Pulmatrix (WKN: A2PD3T) explodiert heute einer der letzten unten gebliebenen No
Agilent Expands Cross-Vendor CDS Instrument Control
Agilent Technologies Inc. (NYSE: A) today announced the latest implementation of its mutual compatibility philosophy. Now, joint customers of Agilent Technologies and Thermo Fisher Scientific can
LION E-Mobility: Nach dem Deal ist vor der Rallye?
LION E-Mobility (WKN: A140QA) hatte mit der kanadischen Firma "The Lion Electric Co." vor Weihnachten einen „Multimillionen-Serienliefervertrag über BMW-Batterien“ geschlossen. Nun gibt das
Agilent Compliance Services Voted No. 1 in Global Survey
Agilent Technologies Inc. (NYSE: A) today announced that the company’s ability to help laboratories comply with government regulations has been ranked second to none in a global survey.
Cell
Savara Granted Breakthrough Therapy Designation for Molgradex for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Molgradex, an inhaled